All In Biotech

Drug Trial Radar · NCT07845266

Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GKL-006 Injection in Combination With TACE in Unresectable Hepatocellular Carcinoma

A Phase 1, Open-label, Controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics of GKL-006 Injection in Combination With Transarterial Chemoembolization (TACE) Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma

Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

13

Actual

Start

Apr 16, 2024

Primary completion

Apr 9, 2025

Study completion Dec 4, 2025

Sponsor

Sponsor type
Industry
First posted
Sep 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase Ia study evaluated the safety and tolerability of a single escalating dose via intravenous infusion of the autologous invariant natural killer T cells (iNKT-cell) product GKL-006 in combination with transarterial chemoembolisation (TACE) in participants with unresectable hepatocellular carcinoma (uHCC). The study aimed to characterise dose-limiting toxicities (DLT), determine the maximum tolerated dose (MTD), and assess pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumour activity.

Conditions

  • Hepatocellular Carcinoma (HCC)
  • Unresectable Hepatocellular Carcinoma

Interventions

  • GKL-006 InjectionBiological

    Autologous iNKT cells collected and reinfused after in vitro cultivation.

  • transarterial chemoembolizationDrug

    A standard locoregional therapy for hepatocellular carcinoma.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose(MTD)of GKL-006Time frame: From the GKL-006 infusion until 28 days.
  2. Incidence of Dose-Limiting Toxicities (DLTs)Time frame: From GKL-006 infusion through Day 28

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Ditan Hospital Chaoyang Campus

    Beijing, Beijing Municipality, China

  • Beijing Youan Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.